The use of THCV and HHC as rare cannabinoids in the treatment of pancreatic cancer has been revealed through in-vitro studies. Use of certain pancreatic cell lines from PDAC has been tested. PANC-1, HPAF-II, AsPc-1, and MIA-PaCa2 cell line were tested against THCV and HHC to generate IC50 values to determine efficacy as possible antineoplastics using the PANC-1, HPAF-II, and AsPC-1 cell lines as shown in figure The compiled data of the compounds tested on various cell lines was compared to PARP inhibitors currently on the market or in clinical trials shown in figure , to provide more objective evidence towards the usage of HHC and THCV as possible pancreatic antineoplastic compounds.